Is bivalirudin FDA-approved, and what does the research show?

What is bivalirudin?

Bivalirudin is a man-made peptide of 20 amino acids, built to bind thrombin, and FDA's label classes it as a direct thrombin inhibitor ¹. Thrombin is the enzyme in blood that turns fibrinogen into fibrin, the mesh that holds a clot together, and that switches on platelets ¹, the cell fragments that plug a wound. A direct thrombin inhibitor binds thrombin itself, and an anticoagulant is any medicine that slows clotting ¹.

The design comes from hirudin, the anti-clotting protein in the saliva of the medicinal leech, and bivalirudin is a synthetic analog of it ², ³. The molecule weighs about 2,180 daltons and is given through a vein ¹. Sandoz holds the Angiomax application today, and generic bivalirudin and a ready-to-use solution, Angiomax RTU, are also approved ⁵, ⁹.

Is bivalirudin FDA-approved?

Yes. Bivalirudin is approved by FDA as a prescription medicine, with "Initial U.S. Approval: 2000" on its label and "Rx only" on the vial ¹. The label indicates it "for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS)" ¹. That is its one indication ¹.

The label's early trials call PCI angioplasty and speak of the dilated vessel ¹. It is the procedure in which a catheter threaded through an artery opens a narrowed heart artery, usually with a stent. Heparin, another anticoagulant, is the comparator in these trials ⁶, ⁷. Heparin-induced thrombocytopenia is a fall in platelets after heparin, and the thrombosis syndrome adds a clot in an artery or vein; the label defines both for its HIT study ¹. For those patients heparin is the problem, and bivalirudin is approved as the anticoagulant in its place ¹.

FDA's Drugs@FDA record, its public register of approved drugs, holds the original new drug application, NDA 020873 for Angiomax, approved December 15, 2000 and now held by Sandoz ⁵. Its marketing status is "Prescription" as of November 9, 2026, the date of Drugs@FDA's data ⁵. Drugs@FDA lists 16 applications with bivalirudin as the active ingredient ⁹. They are 3 NDAs, two of them ready-to-use solutions (the 2019 one still marketed), and 13 generic applications, 2 of them tentatively approved ⁹.

The label is Avenacy's, for a generic, revised June 2026 ¹. The route is intravenous, a single injection into a vein followed by a drip for the length of the procedure, with the care team measuring clotting time as it runs ¹. After a primary PCI, the emergency procedure for a heart attack, the label says, "Patients should remain for at least 24 hours in a facility capable of managing ischemic complications" ¹. Ischemic means harm from blocked blood flow.

See the FDA status of every peptide, updated weekly.

How does bivalirudin work?

Bivalirudin binds thrombin directly at two sites, the catalytic site where thrombin cuts proteins and a second binding site ¹. It binds thrombin that is free in the blood and thrombin already bound in a clot ¹. Blocked thrombin cannot cleave fibrinogen into fibrin, cannot activate the clotting factors V, VIII and XIII that make more thrombin and cross-link the clot, and cannot switch on platelets ¹. The effect is immediate after an intravenous dose, and clotting times return to baseline about one hour after the infusion stops ¹.

The binding is reversible: thrombin slowly cuts one bond in bivalirudin, between its third and fourth amino acids, and recovers its active site ¹. The drug does not bind other plasma proteins or red cells and is broken down by enzymes that cut proteins ¹. Its half-life, the time for the blood level to fall by half, is 25 minutes in PCI patients with normal kidneys ¹. With failing kidneys the body clears it more slowly, by about 70 percent in dialysis patients, so the label has the infusion reduced for them ¹.

What does the research show?

FDA approved bivalirudin on randomized trials against heparin, so its evidence level is "Approved for a use"; the trials since have disagreed ¹, ⁶, ⁷. The label's approval trials, BAT, randomized 4,312 patients with unstable angina, chest pain at rest from a narrowing heart artery, undergoing PCI to bivalirudin or heparin ¹. In hospital, up to seven days, 7.9 percent on bivalirudin and 9.3 percent on heparin died, had a heart attack, had the opened artery close, or worsened ¹. Worsening meant needing revascularization, a repeat procedure to reopen the artery, or a balloon pump to support the heart ¹. The label says the studies "did not demonstrate that bivalirudin was statistically superior to heparin," and that the events were similar in both groups ¹.

A study with no comparison group gave it to 51 PCI patients with HIT or HITTS ¹. After the procedure 48 of them (94 percent) had full flow and under 50 percent narrowing, and no major bleeding was reported ¹.

Studied in people against heparin plus a platelet blocker: REPLACE-2, a double-blind trial, meaning neither patients nor doctors knew the treatment, randomized 6,010 patients having urgent or elective PCI ¹⁰. It ran at 233 hospitals in nine countries and appeared in JAMA's February 2003 issue ¹⁰. Glycoprotein IIb/IIIa inhibitors are drugs that stop platelets from clumping; the heparin arm received one as planned, and 7.2 percent of the bivalirudin arm received one as a rescue ¹⁰.

At 30 days the combined rate of death, heart attack, urgent repeat revascularization or in-hospital major bleeding was 9.2 percent on bivalirudin and 10.0 percent on the heparin regimen ¹⁰. That met the trial's test of no worse, and in-hospital major bleeding was 2.4 against 4.1 percent ¹⁰.

ACUITY, in the New England Journal of Medicine's November 2006 issue, assigned 13,819 patients with moderate- or high-risk acute coronary syndromes, the chest-pain emergencies of a narrowing heart artery ¹¹. Its three regimens were heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin plus the inhibitor, or bivalirudin alone ¹¹. Bivalirudin alone, against the heparin regimen, met the trial's test of no worse on the 30-day rate of death, heart attack or unplanned revascularization, 7.8 against 7.3 percent ¹¹. Major bleeding was lower, 3.0 against 5.7 percent ¹¹.

HORIZONS-AMI, in the same journal's May 2008 issue, randomized 3,602 patients with ST-elevation myocardial infarction, the heart attack from a fully blocked artery, undergoing primary PCI ⁶, ¹². The Cardiovascular Research Foundation sponsored it ¹². Bivalirudin alone, against heparin plus a glycoprotein IIb/IIIa inhibitor, cut the 30-day rate of major bleeding, 4.9 against 8.3 percent ⁶.

It also cut net adverse clinical events, meaning major bleeding or a major heart event, 9.2 against 12.1 percent ⁶. Death from any cause at 30 days was 2.1 percent on bivalirudin and 3.1 percent on heparin plus the inhibitor ⁶. Acute stent thrombosis, a clot in the new stent soon after it is placed, was more frequent on bivalirudin, with no significant difference by 30 days ⁶.

Later trials against heparin alone, rather than heparin plus a platelet blocker, read differently. HEAT-PPCI, an open-label trial, meaning patients and doctors knew the treatment, at one hospital in Liverpool, published online in July 2014, randomized 1,829 patients presenting for primary PCI ⁷. At 28 days, death, stroke, a second heart attack or unplanned repeat treatment of the lesion occurred in 8.7 percent of 905 on bivalirudin ⁷. On heparin it occurred in 5.7 percent of 907, a relative risk of 1.52, about half again as many events ⁷. Major bleeding was 3.5 against 3.1 percent, not a significant difference ⁷.

The authors conclude that heparin "reduces the incidence of major adverse ischaemic events in the setting of PPCI, with no increase in bleeding complications" ⁷. Its funders, as the abstract lists them, were Liverpool Heart and Chest Hospital, the UK National Institute of Health Research, The Medicines Company, AstraZeneca and The Bentley Drivers Club ⁷.

MATRIX, published online in September 2015, randomized 7,213 patients with an acute coronary syndrome expected to have PCI to bivalirudin or heparin ¹³. Death, heart attack or stroke occurred in 10.3 percent on bivalirudin and 10.9 percent on heparin, not a significant difference ¹³. Net adverse clinical events occurred in 11.2 against 12.4 percent, also not significant ¹³. A bivalirudin infusion continued after the procedure did not significantly lower the combined rate of urgent repeat procedures, definite stent thrombosis or net adverse clinical events, 11.0 against 11.9 percent ¹³. The trial was funded by the Medicines Company and Terumo Medical ¹³.

VALIDATE-SWEDEHEART, published online in August 2017, enrolled 6,006 patients having PCI for a heart attack in a registry-based randomized trial in Sweden ⁸. It reflected current practice: wrist-artery access and potent platelet drugs, without planned glycoprotein inhibitors ⁸. At 180 days, death, heart attack or major bleeding occurred in 12.3 percent on bivalirudin and 12.8 percent on heparin ⁸. That is a hazard ratio of 0.96, the ratio of the two rates over time, and major bleeding was 8.6 percent in both arms ⁸.

BRIGHT-4, published online in November 2022, randomized 6,016 patients with ST-elevation heart attacks at 87 centers in China to bivalirudin with a high-dose infusion after PCI or to heparin alone ¹⁴. Death or major bleeding at 30 days was 3.06 percent on bivalirudin and 4.39 percent on heparin, a hazard ratio of 0.69 ¹⁴. Death from any cause was 2.96 against 3.92 percent, major bleeding 0.17 against 0.80 percent, and stent thrombosis 0.37 against 1.10 percent ¹⁴. Its authors open by noting that earlier trials "have reported conflicting results, in part because of treatment with different pharmacological regimens" ¹⁴. The trial was funded by the Chinese Society of Cardiology Foundation and a grant from Jiangsu Hengrui Pharmaceuticals ¹⁴.

Every trial above enrolled patients in a coronary procedure ⁶, ¹⁰, ¹¹, ⁷, ¹³, ⁸, ¹⁴, and the label lists no other use ¹. The label adds that no long-term animal studies of its cancer risk have been done ¹.

What are the side effects?

Bleeding leads. The label's most common adverse reaction, in more than 2 percent, was bleeding, and it says bivalirudin "increases the risk of bleeding" ¹. In the BAT trials, 79 of 2,161 PCI patients on bivalirudin, 3.7 percent, had a major bleed; the label gives no rate for the heparin arm ¹. That meant bleeding inside the skull or behind the abdominal lining, or overt bleeding that cut hemoglobin by more than 3 g/dL or needed more than two units of blood ¹.

The label tells clinicians that an unexplained fall in blood pressure or hematocrit, the share of blood that is red cells, "should lead to serious consideration of a hemorrhagic event" ¹. That consideration includes stopping the drug ¹. Giving it with heparin, warfarin, a blood-thinning pill, clot-dissolving drugs or glycoprotein IIb/IIIa inhibitors was linked to more major bleeding in the trials ¹. Older patients bled more than younger ones; 44 percent of the PCI patients studied were 65 or over ¹.

In the randomized trials the bleeding picture depends on the comparator. Major bleeding was lower on bivalirudin than on heparin plus a glycoprotein IIb/IIIa inhibitor in REPLACE-2 and HORIZONS-AMI, and in ACUITY when given alone ¹⁰, ⁶, ¹¹. Against heparin alone, the later trials found no difference or, in BRIGHT-4, less bleeding on bivalirudin ⁷, ⁸, ¹⁴.

The label's second warning is clotting in the stent. Acute stent thrombosis within four hours "has been observed at a greater frequency in bivalirudin treated patients (1.2%, 36/2889) compared to heparin treated patients (0.2%, 6/2911)" in heart attack patients having primary PCI ¹. One patient in each arm with the clot died ¹.

The third warning is clot formation, "including fatal outcomes," when the drug is used during gamma brachytherapy ¹, a radiation treatment delivered inside the artery. Post-marketing reports add fatal bleeding, anaphylaxis, a severe whole-body allergic reaction, and other allergic reactions, lack of anticoagulant effect, clots during PCI and bleeding into the lungs ¹. They also add cardiac tamponade, blood collecting around the heart and squeezing it, and a raised INR, a clotting blood test ¹.

The label's contraindications, the cases in which it must not be given, are "active major bleeding" and a known allergy, including anaphylaxis, to the drug or its components ¹. Overdoses of up to ten times the recommended dose have been reported, several from infusions not adjusted for failing kidneys, with bleeding and deaths from hemorrhage in some reports ¹. The label says, "There is no known antidote to bivalirudin" ¹.

Safety and effectiveness in children have not been established, and the label has no data on use in pregnant women ¹. Animal studies at up to 3.2 times the human dose by body surface area showed no fetal harm ¹. Among 494 trial subjects tested, two developed antibodies to bivalirudin, neither with signs of allergy ¹.

In sport

Bivalirudin is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency, and neither thrombin inhibitors nor anticoagulants appear on it as a class ¹⁵. The list's method M2.2 covers infusions: it prohibits "Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" ¹⁵. Bivalirudin is given only by injection and infusion into a vein during a coronary procedure ¹.

What JumpstartMD offers

JumpstartMD does not prescribe bivalirudin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.